Use this URL to cite or link to this record in EThOS:
Title: Cellular determinants of raltegravir exposure
Author: Moss, Darren
Awarding Body: University of Liverpool
Current Institution: University of Liverpool
Date of Award: 2012
Availability of Full Text:
Access from EThOS:
Access from Institution:
HIV infection remains a worldwide concern and new drug treatments are required to tackle drug resistance and to reduce drug-associated host toxicity. Raltegravir, a new anti-HIV drug which targets the HIV integrase enzyme, is now being used in anti-HIV treatment and has shown impressive efficacy and low toxicity. However, the drug shows high pharmacokinetic (PK) variability between subjects and it has been difficult to associate PK parameters with treatment outcome. The aim of this thesis was to improve the current understanding of the factors influencing raltegravir PK and cellular exposure using in vitro and in silico techniques.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral